No Data
MediciNova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of MN-166 In ALS At The 35th International Symposium On ALS/MND
Express News | MediciNova Inc - Expects to Complete Patient Assignments by June 2025 With Trial Results Expected in 2026
Express News | MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data
Express News | Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
Volume change rate ranking (9 AM period) - Nishiwa Industries, WealthNavi, etc. are ranked.
※In the volume change rate ranking, you can understand the interest of market participants such as trends in inquiries by comparing the average volume of the past 5 days with the volume on the day of distribution.■Volume Change Rate Top [As of 9:34 on December 3] (Comparison with average volume of the past 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate ＜7342＞ WealthNavi 3479800 10718 5.08 305.83% 0.17% ＜2634＞
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
